Journal
NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 37, Issue 9, Pages 1598-1608Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfaa326
Keywords
anti-CTLA4 antibodies; hypercalcaemia; PTHrp; programmed cell death-1; programmed cell death-ligand 1
Categories
Ask authors/readers for more resources
Immune checkpoint inhibitors (CPIs) are important for treating advanced cancers, but they can also cause immune-related adverse events (irAEs), including hypercalcemia. The causes of CPI-induced hypercalcemia may include endocrine diseases, granulomas, hormonal imbalances, and disease progression. Early recognition and treatment of hypercalcemia are crucial for patient outcomes.
Immune checkpoint inhibitors (CPIs) have recently become a cornerstone for the treatment of different advanced cancers. These drugs have the ability to reactivate the immune system against tumour cells but can also trigger a myriad of side effects, termed immune-related adverse events (irAEs). Although there are numerous reports of CPI-related endocrinopathies, hypercalcaemia as a suspected irAE is not well documented. The mechanisms of CPI hypercalcaemia are not clearly established. However, in our review, four distinct causes emerged: endocrine disease-related, sarcoid-like granuloma, humoral hypercalcaemia due to parathyroid-related hormone and hyperprogressive disease following CPI initiation. Prompt recognition of hypercalcaemia and the institution of therapy can be lifesaving, affording the opportunity to address the underlying aetiology. In this review we discuss the incidence, diagnosis and management of immune-related hypercalcaemia in oncological patients receiving CPI agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available